Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
Introduction: Durvalumab 10 mg/kg every 2 weeks for 1 year after chemoradiation has improved overall survival (OS) in unresectable stage III NSCLC. Subsequently, a 20 mg/kg 4-weekly regimen was approved. The study goal was to compare the efficacy and toxicity of the two regimens. Methods: All patien...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-05-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364322000406 |
| _version_ | 1818213921504362496 |
|---|---|
| author | Marie-Hélène Denault, MD, MSc Shelley Kuang, MD, FRCPC Aria Shokoohi, BSc Bonnie Leung, MN-NP Mitchell Liu, MDCM, FRCPC Eric Berthelet, MD, FRCPC Janessa Laskin, MD, FRCPC Sophie Sun, MD, FRCPC Tina Zhang, MD, FRCPC Barbara Melosky, MD, FRCPC Cheryl Ho, MD, FRCPC |
| author_facet | Marie-Hélène Denault, MD, MSc Shelley Kuang, MD, FRCPC Aria Shokoohi, BSc Bonnie Leung, MN-NP Mitchell Liu, MDCM, FRCPC Eric Berthelet, MD, FRCPC Janessa Laskin, MD, FRCPC Sophie Sun, MD, FRCPC Tina Zhang, MD, FRCPC Barbara Melosky, MD, FRCPC Cheryl Ho, MD, FRCPC |
| author_sort | Marie-Hélène Denault, MD, MSc |
| collection | DOAJ |
| description | Introduction: Durvalumab 10 mg/kg every 2 weeks for 1 year after chemoradiation has improved overall survival (OS) in unresectable stage III NSCLC. Subsequently, a 20 mg/kg 4-weekly regimen was approved. The study goal was to compare the efficacy and toxicity of the two regimens. Methods: All patients with NSCLC treated with curative-intent chemoradiation followed by durvalumab from March 1, 2018 to December 31, 2020 at BC Cancer, British Columbia, Canada were included in this retrospective review. Durvalumab dosing schedule, toxicity, progression, and OS were collected. Comparisons between treatment groups were made using chi-square and independent t tests. Kaplan-Meier curves and log-rank test were used to analyze OS. Results: A total of 152 patients were included in the 2-weekly group and 53 patients in the 4-weekly group. The median follow-up was 19.7 months and 12.0 months, respectively. The median OS was not reached, but 12-month survival rates were 88.4% versus 85.2% (p = 0.55). Toxicity profiles were similar in terms of sites and severity. Conclusions: There was no significant difference in efficacy or toxicity between the 2-weekly and 4-weekly durvalumab in this cohort of patients with advanced NSCLC previously treated with curative-intent chemoradiation. |
| first_indexed | 2024-12-12T06:11:58Z |
| format | Article |
| id | doaj.art-bde7a2a808be4a1aa4e9265d197f84cb |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-12-12T06:11:58Z |
| publishDate | 2022-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-bde7a2a808be4a1aa4e9265d197f84cb2022-12-22T00:35:08ZengElsevierJTO Clinical and Research Reports2666-36432022-05-0135100316Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief ReportMarie-Hélène Denault, MD, MSc0Shelley Kuang, MD, FRCPC1Aria Shokoohi, BSc2Bonnie Leung, MN-NP3Mitchell Liu, MDCM, FRCPC4Eric Berthelet, MD, FRCPC5Janessa Laskin, MD, FRCPC6Sophie Sun, MD, FRCPC7Tina Zhang, MD, FRCPC8Barbara Melosky, MD, FRCPC9Cheryl Ho, MD, FRCPC10Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada; Quebec Heart and Lung Institute, Québec City, Québec, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, Canada; Quebec Heart and Lung Institute, Québec City, Québec, Canada; Radiation Oncology, BC Cancer, Vancouver, British Columbia, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, Canada; Quebec Heart and Lung Institute, Québec City, Québec, Canada; Radiation Oncology, BC Cancer, Vancouver, British Columbia, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, Canada; Quebec Heart and Lung Institute, Québec City, Québec, Canada; Radiation Oncology, BC Cancer, Vancouver, British Columbia, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, CanadaMedical Oncology, BC Cancer, Vancouver, British Columbia, Canada; Corresponding author. Address for correspondence: Cheryl Ho, MD, FRCPC, BC Cancer, Vancouver Center, 600 West 10th Avenue, Vancouver, BC V5Z 4E6 Canada.Introduction: Durvalumab 10 mg/kg every 2 weeks for 1 year after chemoradiation has improved overall survival (OS) in unresectable stage III NSCLC. Subsequently, a 20 mg/kg 4-weekly regimen was approved. The study goal was to compare the efficacy and toxicity of the two regimens. Methods: All patients with NSCLC treated with curative-intent chemoradiation followed by durvalumab from March 1, 2018 to December 31, 2020 at BC Cancer, British Columbia, Canada were included in this retrospective review. Durvalumab dosing schedule, toxicity, progression, and OS were collected. Comparisons between treatment groups were made using chi-square and independent t tests. Kaplan-Meier curves and log-rank test were used to analyze OS. Results: A total of 152 patients were included in the 2-weekly group and 53 patients in the 4-weekly group. The median follow-up was 19.7 months and 12.0 months, respectively. The median OS was not reached, but 12-month survival rates were 88.4% versus 85.2% (p = 0.55). Toxicity profiles were similar in terms of sites and severity. Conclusions: There was no significant difference in efficacy or toxicity between the 2-weekly and 4-weekly durvalumab in this cohort of patients with advanced NSCLC previously treated with curative-intent chemoradiation.http://www.sciencedirect.com/science/article/pii/S2666364322000406Advanced non–small cell lung cancerDurvalumabAdjuvantImmune checkpoint inhibitorsImmune-related toxicity |
| spellingShingle | Marie-Hélène Denault, MD, MSc Shelley Kuang, MD, FRCPC Aria Shokoohi, BSc Bonnie Leung, MN-NP Mitchell Liu, MDCM, FRCPC Eric Berthelet, MD, FRCPC Janessa Laskin, MD, FRCPC Sophie Sun, MD, FRCPC Tina Zhang, MD, FRCPC Barbara Melosky, MD, FRCPC Cheryl Ho, MD, FRCPC Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report JTO Clinical and Research Reports Advanced non–small cell lung cancer Durvalumab Adjuvant Immune checkpoint inhibitors Immune-related toxicity |
| title | Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report |
| title_full | Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report |
| title_fullStr | Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report |
| title_full_unstemmed | Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report |
| title_short | Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report |
| title_sort | comparison of 2 weekly versus 4 weekly durvalumab consolidation for locally advanced nsclc treated with chemoradiotherapy a brief report |
| topic | Advanced non–small cell lung cancer Durvalumab Adjuvant Immune checkpoint inhibitors Immune-related toxicity |
| url | http://www.sciencedirect.com/science/article/pii/S2666364322000406 |
| work_keys_str_mv | AT mariehelenedenaultmdmsc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT shelleykuangmdfrcpc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT ariashokoohibsc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT bonnieleungmnnp comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT mitchellliumdcmfrcpc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT ericbertheletmdfrcpc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT janessalaskinmdfrcpc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT sophiesunmdfrcpc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT tinazhangmdfrcpc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT barbarameloskymdfrcpc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport AT cherylhomdfrcpc comparisonof2weeklyversus4weeklydurvalumabconsolidationforlocallyadvancednsclctreatedwithchemoradiotherapyabriefreport |